Soluble programmed cell death ligand-1 as a possible predictive marker for anti-programmed cell death-1 antibody therapy against non-small lung cancers

Soluble programmed cell death ligand-1 as a possible predictive marker for anti-programmed cell death-1 antibody therapy against non-small lung cancers - Soluble PD-L1 as a possible predictive marker for anti-PD-1 mAb therapy against NSCLCs

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000023540

Enrollment

Registered

2016-08-08

Start date

2016-07-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: NSCLC patients over 20 years old who will be treated with Nivolumab and have agreed to examine their own blood sPD-L1 level by a document.

Exclusion criteria

Exclusion criteria: NSCLC patients who will be treated with Nivolumab but have not agreed to examine their own blood sPD-L1 level.

Design outcomes

Primary

Measure	Time frame
Blood sPD-L1 level is a predictive marker for the clinical results of anti-PD-1 mAb therapy agaist NSCLCs.	—

Countries

Japan

Contacts

Public ContactSadamu Homma

Jikei University School of Medicine Division of Oncology

sahya@jikei.ac.jp03-3433-1111

Outcome results